Petitions the Federal Trade Commission to set aside a 1973 consent order against Foremost-McKesson covering trade shows. The original order settled charges that the wholesaler accepted certain promotional allowances from suppliers. Under the order, McKesson is prohibited from receiving in connection with trade shows promotional services, facilities, or "anything of value" from suppliers that is not available to other wholesalers. Also, McKesson cannot offer inducements to customers to attend its annual trade show based on the size of the customer's business with McKesson. In 1983, McKesson settled a consent decree for $300,000 after FTC charged the company with violating the order.
You may also be interested in...
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Pacific Biosciences of California and Aziyo Biologics both acquire new finance chiefs; Illumina hires a new chief marketing officer; WishBone Medical president moves over to take helm at Electromedical Products International; and more.
Complex active ingredients, formulations, routes of delivery, and drug-device combination products are to receive greater attention as part of attempts to facilitate competition after the US FDA awarded a $5m grant to establish a dedicated research center.